Cogent Biosciences DEF 14A: Executive Compensation Details
Ticker: COGT · Form: DEF 14A · Filed: Apr 22, 2025 · CIK: 1622229
| Field | Detail |
|---|---|
| Company | Cogent Biosciences, INC. (COGT) |
| Form Type | DEF 14A |
| Filed Date | Apr 22, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, sec-filing
TL;DR
Cogent Biosciences dropped its 2024 exec comp details. Check out the equity awards.
AI Summary
Cogent Biosciences, Inc. filed its DEF 14A on April 22, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted, outstanding, and vested for both principal executive officers (PEO) and non-PEO named executive officers.
Why It Matters
This filing provides transparency into how Cogent Biosciences compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This is a routine annual filing providing information on executive compensation and does not indicate any immediate financial distress or significant operational changes.
Key Players & Entities
- Cogent Biosciences, Inc. (company) — Filer of the DEF 14A
- 20250422 (date) — Filing date of the DEF 14A
- 2024-12-31 (date) — Fiscal year end for compensation details
- Unum Therapeutics Inc. (company) — Former company name
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by a company to solicit proxies from shareholders for an upcoming annual or special meeting of shareholders. It contains detailed information about matters to be voted on, including executive compensation, director elections, and other corporate governance issues.
When was this DEF 14A filed by Cogent Biosciences, Inc.?
This DEF 14A filing was filed on April 22, 2025.
What fiscal year do the compensation details in this filing primarily cover?
The compensation details in this filing primarily cover the fiscal year ending December 31, 2024.
What type of information is typically found in the compensation tables of a DEF 14A?
The compensation tables typically include details on base salary, bonus, stock awards, option awards, non-equity incentive plan compensation, and changes in pension value and nonqualified deferred compensation for named executive officers.
Has Cogent Biosciences, Inc. undergone any name changes?
Yes, the company was formerly known as Unum Therapeutics Inc. and Unum Therapeutics, Inc., with name changes occurring on April 2, 2018, and October 14, 2014, respectively.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 22, 2025 regarding Cogent Biosciences, Inc. (COGT).